While in the multiday, several-dose arm, baseline microbiota was equivalent among topics that obtained ibezapolstat as opposed with vancomycin. At Day ten of dosing, differential abundance analysis and β-variety shown a distinct difference between the microbiome in subjects given vancomycin in